The full repayment of the Sanofi Development Balance removes a drag on collaboration profits starting Q3, providing a structural tailwind to earnings. With double-digit top- and bottom-line growth, raised gross margin guidance, and a $2.5B buyback authorization, the stock should re-rate higher. Key catalysts to watch: cemdisiran PDUFA in November 2026 and Dupixent CSU expansion in pediatrics.
Price Chart
Executive Summary
Regeneron reported Q2 2026 revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, driven by Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%). Guidance was modestly tightened higher on R&D and gross margins, and the Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3. The strong beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.
Key Financial Metrics
Key Facts
- Total revenues $4.29B, +17% YoY vs $3.68B
- Non-GAAP EPS $14.29, +11% YoY, 40.1% above $10.20 consensus
- Dupixent global net sales $6.0B, +38% YoY (record)
- EYLEA HD U.S. net sales $596M, +52% YoY (record)
- Libtayo global net sales $489M, +30% YoY (record)
- Sanofi collaboration revenue $2.17B, +51% YoY; Development Balance fully repaid
- GAAP net income $1.30B, -7% YoY due to $127M IPR&D charge and higher tax rate
- 2026 guidance: GAAP R&D narrowed to $6.50-6.635B; non-GAAP gross margin raised to 84-85%
- Share repurchases of $1.2B in Q2, $2.0B YTD; $2.5B remaining
- Cemdisiran NDA accepted for priority review in gMG, PDUFA Nov 2026
Financial Impact
Non-GAAP EPS beat consensus by $4.09 (40.1%); revenue beat by $460M (12.0%)
Risk Factors
- Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
- EYLEA franchise U.S. sales declined 12% YoY as patients transition to EYLEA HD at lower net price
- GAAP net income declined 7% YoY due to $127M IPR&D charge and higher effective tax rate (15.1% vs 8.4%)
- Patent litigation related to EYLEA remains an overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000872589-26-000023 |
| Document: 0000872589-26-000023-index-headers.html | 0000872589-26-000023 |
| Document: 0000872589-26-000023-index.html | 0000872589-26-000023 |
| Document: 0000872589-26-000023.txt | 0000872589-26-000023 |
| 8-K Data (Synthetic) | 0000872589-26-000023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $781.49 | ▼ −7.35% | ▼ −6.20% | $736.78 (−12.65%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $799.08 | ▼ −3.55% | ▼ −4.02% | $736.78 (−11.07%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $807.71 | ▼ −2.29% | ▼ −3.40% | $736.78 (−10.87%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $840.84 | ▲ +5.37% | ▲ +5.81% | $736.78 (−7.67%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.57 | ▲ +1.33% | ▲ +1.73% | $736.78 (−7.56%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $736.78 (−0.21%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $736.78 (−0.21%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $759.24 | ▼ −9.21% | ▼ −6.95% | $736.78 (−5.98%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $651.91 | ▼ −3.66% | ▼ −2.97% | $736.78 (+8.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access